TY - JOUR
T1 - Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib
AU - Quintás-Cardama, Alfonso
AU - Kantarjian, Hagop
AU - Shan, Jianqin
AU - Jabbour, Elias
AU - Abruzzo, Lynne V.
AU - Verstovsek, Srdan
AU - Garcia-Manero, Guillermo
AU - O'Brien, Susan
AU - Cortes, Jorge
PY - 2011/11/15
Y1 - 2011/11/15
N2 - BACKGROUND: Deletions of derivative chromosome 9 are a poor prognostic factor in patients with chronic myeloid leukemia (CML) treated with hydroxyurea, interferon, or stem cell transplantation. Imatinib may overcome the adverse prognostic impact of deletions of derivative chromosome 9. METHODS: A study was undertaken to investigate the prognostic impact of deletions of derivative chromosome 9 in 353 patients with CML receiving the second generation tyrosine kinase inhibitors (TKIs) nilotinib (n = 161) or dasatinib (n = 192). RESULTS: Deletion of derivative chromosome 9 status was determined in 245 (69%). Twenty-eight (11%) patients, 22 in chronic phase, 4 in accelerated phase, and 2 in blast phase, carried deletions of derivative chromosome 9, including 17 receiving nilotinib and 11 receiving dasatinib (P =.47). Overall survival (OS) at 24 months was similar between patients with or without deletions of derivative chromosome 9 (70% vs 71%, P =.76). For patients in chronic phase, no significant differences in overall major cytogenetic response (77% vs 82%, P =.57) or complete cytogenetic response (77% vs 81%, P =.71) rates were observed between patients with or without deletions of derivative chromosome 9. At 24 months, patients with CML in chronic phase without deletions of derivative chromosome 9 had improved event-free survival (EFS) (88% vs 66%, P =.07) and OS (96% vs 82%; P =.08) compared with those carrying deletions of derivative chromosome 9. However, multivariate analysis established second-line versus frontline second generation TKI therapy as the only adverse prognostic factor for EFS and increased bone marrow blast burden and older age as independent adverse prognostic factors for OS. CONCLUSIONS: Deletions of derivative chromosome 9 do not appear to be an independent risk factor for survival among patients with CML in chronic phase receiving second generation TKIs. Cancer
AB - BACKGROUND: Deletions of derivative chromosome 9 are a poor prognostic factor in patients with chronic myeloid leukemia (CML) treated with hydroxyurea, interferon, or stem cell transplantation. Imatinib may overcome the adverse prognostic impact of deletions of derivative chromosome 9. METHODS: A study was undertaken to investigate the prognostic impact of deletions of derivative chromosome 9 in 353 patients with CML receiving the second generation tyrosine kinase inhibitors (TKIs) nilotinib (n = 161) or dasatinib (n = 192). RESULTS: Deletion of derivative chromosome 9 status was determined in 245 (69%). Twenty-eight (11%) patients, 22 in chronic phase, 4 in accelerated phase, and 2 in blast phase, carried deletions of derivative chromosome 9, including 17 receiving nilotinib and 11 receiving dasatinib (P =.47). Overall survival (OS) at 24 months was similar between patients with or without deletions of derivative chromosome 9 (70% vs 71%, P =.76). For patients in chronic phase, no significant differences in overall major cytogenetic response (77% vs 82%, P =.57) or complete cytogenetic response (77% vs 81%, P =.71) rates were observed between patients with or without deletions of derivative chromosome 9. At 24 months, patients with CML in chronic phase without deletions of derivative chromosome 9 had improved event-free survival (EFS) (88% vs 66%, P =.07) and OS (96% vs 82%; P =.08) compared with those carrying deletions of derivative chromosome 9. However, multivariate analysis established second-line versus frontline second generation TKI therapy as the only adverse prognostic factor for EFS and increased bone marrow blast burden and older age as independent adverse prognostic factors for OS. CONCLUSIONS: Deletions of derivative chromosome 9 do not appear to be an independent risk factor for survival among patients with CML in chronic phase receiving second generation TKIs. Cancer
KW - BCR-ABL1
KW - dasatinib
KW - deletion
KW - derivative chromosome 9
KW - nilotinib
UR - http://www.scopus.com/inward/record.url?scp=80555155591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80555155591&partnerID=8YFLogxK
U2 - 10.1002/cncr.26147
DO - 10.1002/cncr.26147
M3 - Article
C2 - 21523765
AN - SCOPUS:80555155591
SN - 0008-543X
VL - 117
SP - 5085
EP - 5093
JO - Cancer
JF - Cancer
IS - 22
ER -
